Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May-Aug;5(2):106-10.
doi: 10.4103/2229-516X.157155.

A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris

Jasleen Kaur  1 , Vijay K Sehgal  1 , Anita K Gupta  1 , Surinder P Singh  2
Affiliations

A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris

Jasleen Kaur et al. Int J Appl Basic Med Res. 2015 May-Aug.

Abstract

Background: The combinations of topical keratolytics with anti-microbials and topical retinoids with antimicrobials are commonly prescribed in the treatment of acne.

Aim: The present study was undertaken with the aim of comparing the efficacy and safety of topical benzoyl peroxide and clindamycin versus topical benzoyl peroxide and nadifloxacin versus topical tretinoin and clindamycin in patients of acne vulgaris.

Materials and methods: 100 patients between 15 and 35 years having ≥2 and ≤30 inflammatory and/or noninflammatory lesions with Investigator's Global Assessment (IGA) score 2/3 were randomly divided into 3 groups. Group A was prescribed benzoyl peroxide 2.5% gel and clindamycin 1% gel, Group B was prescribed benzoyl peroxide 2.5% gel and nadifloxacin 1% cream and Group C was prescribed tretinoin 0.025% and clindamycin 1% gel. Total number of lesions and adverse effects during the treatment were assessed at 0, 4, 8, 12 weeks with IGA score.

Results: There was statistically significant reduction in total number of lesions with better improvement in Group A. Adverse drug reactions during the study showed a better safety profile of Group B which is found to be statistically significant also.

Conclusion: These findings confirm that Group A is more efficacious and Group B is safest among the other two groups.

Keywords: Adverse drug reactions; Investigator's Global Assessment score; anti-microbials; keratolytics; retinoids.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Comparison of all the three groups (benzoyl peroxide 2.5% gel and clindamycin 1% gel, benzoyl peroxide 2.5% gel and nadifloxacin 1% cream, tretinoin 0.025% and clindamycin 1% gel) on the mean of the number of noninflammatory lesions
Figure 2
Figure 2
Comparison of all the three groups (benzoyl peroxide 2.5% gel and clindamycin 1% gel, benzoyl peroxide 2.5% gel and nadifloxacin 1% cream, tretinoin 0.025% and clindamycin 1% gel) on the mean of the number of inflammatory lesions
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tutakne MA, Vaishampayan SS. Acne, rosacea and perioral dermatitis. In: Valia RG, Valia AR, editors. IAVDL Textbook of Dermatology. 3rd ed. Mumbai: Bhalani Publication House; 2008. pp. 839–43.
    1. Zaenglein AL, Graber EM, Thiboutot DM, Strauss JS. Acne vulgaris and acneiform eruption. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Lefell DJ, editors. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York: McGraw Hill Companies; 2007. pp. 687–703.
    1. Pretsch A, Nagl M, Schwendinger K, Kreiseder B, Wiederstein M, Pretsch D, et al. Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria. PLoS One. 2014;9:e97929. - PMC - PubMed
    1. Gollnick HP, Zouboulis CC. Not all acne is acne vulgaris. Dtsch Arztebl Int. 2014;111:301–12. - PMC - PubMed
    1. Gregoriou S, Kritsotaki E, Katoulis A, Rigopoulos D. Use of tazarotene foam for the treatment of acne vulgaris. Clin Cosmet Investig Dermatol. 2014;7:165–70. - PMC - PubMed